Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 1997

View Archived Issues

New agent for breast cancer in development at Zenyaku Kogyo

Oxygen carrier tested in patients with sickle cell disease

AmBisome approved in Russia

Fujisawa Foundation gives research grants

HemoCleanse submits 510(k) for ThermoChem-HT

R&D partnership announced between Helix BioPharma and PENCE

DiagnoCure granted U.S. patent for nanoerythrosomes

Patent for dry powder inhaler issued to TheraTech

CytoGam approved for marketing in Canada

Texas Biotechnology and SmithKline Beecham form marketing alliance for Novastan

IL-1ra tested for corneal transplant

YH-439 metabolites identified in rat urine

Labopharm: Q1 1997 highlights

Pain management: How to take control

DaunoXome approved in Russia

Genzyme Transgenics' cancer vaccine elicits immune response in myeloma patients

Results of RPR Gencell's gene therapy for Parkinson's disease reported

AVE seeks FDA approval for stent products

New analgesic/antiinflammatory compounds from Korea

First launch for new angiotensin II blocker

NMDA antagonist enters phase I for epilepsy

Atypical beta-adrenoceptor agonists from Glaxo Wellcome

Transkaryotic Therapies allowed European patent for gene therapy technology

Algos and NIDA enter into collaboration for heroin addiction treatment

Seragen grants U.S. Surgical option to restenosis product

Shionogi's beta-lactam antibiotic launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.